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OBJECTIVES We sought to determine whether improving coupling between glucose oxidation and
glycolysis by stimulating glucose oxidation during reperfusion enhances postischemic recovery
of hypertrophied hearts.
BACKGROUND Low rates of glucose oxidation and high glycolytic rates are associated with greater
postischemic dysfunction of hypertrophied as compared with nonhypertrophied hearts.
METHODS Heart function, glycolysis and glucose oxidation were measured in isolated working control
and hypertrophied rat hearts for 30 min before 20 min of global, no-flow ischemia and during
60 min of reperfusion. Selected control and hypertrophied hearts received 1.0 mmol/liter
dichloroacetate (DCA), an activator of pyruvate dehydrogenase, at the time of reperfusion to
stimulate glucose oxidation.
RESULTS In the absence of DCA, glycolysis was higher and glucose oxidation and recovery of function
were lower in hypertrophied hearts than in control hearts during reperfusion. Dichloroacetate
stimulated glucose oxidation during reperfusion approximately twofold in both groups, while
significantly reducing glycolysis in hypertrophied hearts. It also improved function of both
hypertrophied and control hearts. In the presence of DCA, recovery of function of
hypertrophied hearts was comparable to or better than that of untreated control hearts.
CONCLUSIONS Dichloroacetate, given at the time of reperfusion, normalizes postischemic function of
hypertrophied rat hearts and improves coupling between glucose oxidation and glycolysis by
increasing glucose oxidation and decreasing glycolysis. These findings support the hypothesis
that low glucose oxidation rates and high glycolytic rates contribute to the exaggerated
postischemic dysfunction of hypertrophied hearts. (J Am Coll Cardiol 2000;36:1378–85) ©
2000 by the American College of Cardiology
Postischemic left ventricular dysfunction is greater in hy-
pertrophied hearts than in nonhypertrophied hearts (1–6).
Alterations in myocardial energy metabolism, particularly
glucose metabolism, are thought to contribute to the in-
creased susceptibility of hypertrophied hearts to injury after
ischemia and reperfusion (1–6). During reperfusion of the
hypertrophied heart, glycolysis and oxidation of glucose,
fatty acid and lactate recover to preischemic values (3). This
finding indicates that impairments in glycolysis and oxida-
tive metabolism are not responsible for the greater postisch-
emic left ventricular dysfunction of hypertrophied as com-
pared with nonhypertrophied hearts.
See page 1386
Although overall energy metabolism is not impaired, the
pattern of energy substrate use is altered and may influence
postischemic left ventricular function in the hypertrophied
heart (3,4). Rates of glycolysis are accelerated in hypertro-
phied as compared with nonhypertrophied hearts during
postischemic reperfusion (3,4). However, rates of glucose
oxidation during reperfusion are not correspondingly in-
creased in hypertrophied hearts (3,4). Under normal cir-
cumstances, the increased production of pyruvate accompa-
nying accelerated rates of glycolysis should lead to higher
rates of glucose oxidation by way of pyruvate-induced
activation of pyruvate dehydrogenase (PDH), a key enzyme
involved in glucose oxidation in mammalian tissues (7,8).
Thus, relative to glycolysis, glucose oxidation is substantially
lower than normal in the hypertrophied heart during reper-
fusion.
These low rates of glucose oxidation result in a dramatic
imbalance (or uncoupling) between glycolysis and glucose
oxidation in the hypertrophied heart that is much greater
than that seen in the nonhypertrophied heart (9,10). In
nonhypertrophied hearts, low rates of glucose oxidation and
increased uncoupling between glycolysis and glucose oxida-
tion are detrimental during reperfusion after ischemia
(9,10). Stimulation of glucose oxidation, which improves
coupling between glycolysis and glucose oxidation, is clearly
beneficial to the nonhypertrophied heart during reperfusion
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after ischemia (9–14). Taken together, these data suggest
that low rates of glucose oxidation, high glycolytic rates and
the accompanying accentuated uncoupling between glycol-
ysis and glucose oxidation are responsible for the increased
postischemic dysfunction of hypertrophied as compared
with nonhypertrophied hearts.
Therefore, we undertook this study to test the hypothesis
that improving coupling between glucose oxidation and
glycolysis by stimulating glucose oxidation enhances post-
ischemic function of the hypertrophied heart.
EXPERIMENTAL METHODS
Animal model. As previously described (3,4,15), a mild
pressure overload cardiac hypertrophy was induced in male
Sprague-Dawley rats by constriction of the suprarenal ab-
dominal aorta. In control rats, the aorta was isolated but not
constricted. Food and water were available as desired. These
experiments were approved by the University of British
Columbia’s Committee on Animal Care in accordance with
guidelines set by the Canadian Council on Animal Care.
Isolated heart preparation. As described (3,4,15), hearts
from halothane-anesthetized rats were perfused as isolated
working preparations at a preload of 11.5 mm Hg and an
afterload of 80 mm Hg with 100 ml of Krebs-Henseleit
solution eight weeks after the operation. The solution,
which contained 1.2 mmol/liter palmitate prebound to 3%
albumin, 5.5 mmol/liter (5-3H)-glucose (31,838 6 1,132
disintegrations per minute [dpm]/mmol glucose), (U-14C)-
glucose (40,611 6 1,381 dpm/mmol glucose), 0.5 mmol/
liter lactate, 2.5 mmol/liter calcium and 100 mU/liter
insulin, continuously circulated through the closed perfu-
sion system. The solution was oxygenated with 95% oxygen
and 5% carbon dioxide and maintained at 37°C throughout
the perfusion. A high concentration of palmitate was used
to recapitulate the levels of fatty acids observed in vivo
during ischemia and reperfusion (16).
A pressure transducer (Viggo-Spectramed, Oxnard, Cal-
ifornia) inserted in the afterload line was used to measure
heart rate and peak systolic pressure. Cardiac output and
aortic flow were measured by means of external flow probes
(Transonic Systems Inc., Ithaca, New York) on the preload
and aortic outflow lines, respectively. Coronary flow was
calculated as the difference between cardiac output and
aortic flow. The external work performed by the heart was
expressed as the rate–pressure product (calculated as the
product of heart rate and peak systolic pressure) and
hydraulic work (calculated as the product of cardiac output
and peak systolic pressure) (11,15).
Perfusion protocol. Spontaneously beating hearts were
subjected to 30 min of normoxic, nonischemic perfusion
followed by 20 min of global (no-flow) normothermic
ischemia and 60 min of normoxic reperfusion. This severity
of ischemia was chosen because it maximizes the number of
hearts that recover (approximately two-thirds) and reliably
causes significant postischemic myocardial dysfunction
(30% to 60% of preischemic function). Reperfusion was
initiated by unclamping the preload and afterload lines.
Perfusate in these lines was replenished throughout the
ischemic period. As such, hearts received warm, oxygenated
perfusate (with or without dichloroacetate [DCA]) imme-
diately at the onset of reperfusion. When administered,
DCA (1.0 mmol/liter) was introduced into the recirculating
perfusate 5 min before the end of ischemia to achieve
complete mixing before reperfusion. We exclusively deter-
mined the effect of DCA on postischemic function when
administered only at reperfusion, because not only is this the
most clinically relevant situation, but it also has been shown
that DCA and insulin are detrimental to postischemic
recovery when given together before ischemia (9). The
exaggerated dysfunction under these circumstances is likely
a consequence of increased proton and lactate accumulation
during ischemia (9,12). A subset of this series was perfused
nonischemically for 30 min in the presence or absence of 1.0
mmol/liter DCA.
A separate series of control and hypertrophied hearts was
also studied in which the hearts were paced electrically (300
beats/min) during reperfusion to account for differences in
heart rate. The paced hearts were perfused exactly as the
first series, except that glycolysis and glucose oxidation were
not measured.
Left ventricular function was measured every 10 min of
nonischemic perfusion and at intervals of 5, 10, 15, 20, 40
and 60 min during reperfusion. At the end of the nonisch-
emic and reperfusion periods, the hearts were quickly frozen
using tongs cooled to the temperature of liquid nitrogen.
The frozen tissue was weighed to determine ventricular
weight, powdered and stored at 270°C. The atrial tissue
remaining was dried, weighed and used in the calculation of
the total heart weight. A portion of the ventricular tissue
was dried to determine the dry/wet ratio used in the
calculation of the total dry weight of the heart. Glycogen
content was determined in representative samples of frozen
myocardium by standard techniques.
Measurement of glucose oxidation and glycolysis. Gly-
colysis and glucose oxidation rates were determined as
previously described (3,4,15). Glycolysis was determined by
measuring the rate at which 3H2O was released from
(5-3H)-glucose at the triose phosphate isomerase and eno-
lase steps of glycolysis. Glucose oxidation was measured by
quantitative collection of 14CO2 liberated from (U-
14C)-
Abbreviations and Acronyms
ANOVA 5 analysis of variance
ATP 5 adenosine triphosphate
DCA 5 dichloroacetate
NAD 5 oxidized nicotinamide adenine dinucleotide
NADH2 5 reduced nicotinamide adenine dinucleotide
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PDK 5 pyruvate dehydrogenase kinase
pHi 5 intracellular H1 concentration
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glucose by mitochondrial pyruvate, isocitrate and oxogluta-
rate dehydrogenases.
Perfusate and gaseous samples were taken every 10 min of
nonischemic perfusion and at intervals of 5, 10, 15, 20, 40
and 60 min during reperfusion. Samples for determination
of glycolysis and glucose oxidation were ultimately placed in
vials containing scintillation cocktail and counted by stan-
dard techniques. Glycolysis and glucose oxidation reflect the
metabolism of exogenous glucose, because the contribution
of glycogen was not directly measured in these experiments.
Statistical analysis. Analysis was performed using SPSS
version 7.0. Weight data were analyzed using two-way
analysis of variance (ANOVA). Left ventricular function,
glucose oxidation and glycolysis were examined using two-
way repeated measures ANOVA. A log transformation of
data was used, when necessary, to satisfy homogeneity of
variance assumptions for ANOVA. The sequential rejective
Bonferroni procedure was used to correct for multiple
comparisons and tests (17). A corrected p value .0.05 was
considered as nonsignificant. Data are expressed as the
mean value 6 SEM.
RESULTS
Heart weight and body weight data. There were no
differences in heart weight or body weight between treated
and untreated control groups or between treated and un-
treated aortic-banded groups (data not shown). The heart
weight of the aortic-banded rats (2.1 6 0.1 g, n 5 39) was
greater than that of the control rats (1.9 6 0.1 g, n 5 34,
p , 0.05). Body weight was not different between aortic-
banded (488 6 11 g) and control rats (479 6 7 g, p 5 NS).
Mechanical function of control and hypertrophied
hearts. Before ischemia, significant differences were not
observed in either series—that is, between control hearts
with and without DCA during reperfusion or between
hypertrophied hearts with and without DCA during reper-
fusion (data not shown). In spontaneously beating hearts, all
variables of function, except peak systolic pressure, were
lower in hypertrophied hearts than in control hearts before
ischemia (Table 1, Fig. 1). During reperfusion, all func-
tional variables were lower in untreated, spontaneously
beating control and hypertrophied hearts, as compared with
corresponding preischemic values (Table 1, Fig. 1). With
the exception of hydraulic work and peak systolic pressure,
left ventricular functional indexes were lower in untreated
hypertrophied hearts than in untreated control hearts during
reperfusion (Table 1, Fig. 1).
Treatment of spontaneously beating control and hyper-
trophied hearts with DCA during reperfusion improved
most functional variables in both groups, as compared with
corresponding values in untreated hearts (Table 1, Fig. 1).
Heart function and coronary flow increased in DCA-treated
hypertrophied hearts to values that were significantly greater
than or comparable to those in untreated control hearts
(Table 1, Fig. 1). However, hydraulic work and coronary
flow were significantly lower in DCA-treated hypertrophied
hearts than in DCA-treated control hearts. Exposure of
nonischemic hearts to DCA also significantly improved
function in both groups (Table 2).
Mechanical function of control and hypertrophied rat
hearts that were paced during reperfusion is summarized in
Table 3. The results of this series were very similar to those
of the spontaneously beating control and hypertrophied
hearts during reperfusion (Table 1). Dichloroacetate im-
proved functional recovery during reperfusion of both con-
trol and hypertrophied hearts, as compared with corre-
sponding values in untreated hearts. In the presence of
DCA, contractile function during reperfusion of paced
hypertrophied hearts was comparable to that seen in un-
treated, paced control hearts. Except for peak systolic
pressure, contractile function of DCA-treated, paced con-
trol hearts was significantly greater than that of DCA-
treated, paced hypertrophied hearts during reperfusion.
Myocardial glucose metabolism. GLYCOLYSIS. Rates of
glycolysis were accelerated in hypertrophied hearts as com-
pared with control hearts during the preischemic period
















Heart rate (beats/min) 247 6 5.0 228 6 6.8* 229 6 19.5* 155 6 27.0*†‡ 262 6 6.6†‡ 252 6 6.4†§
Peak systolic pressure (mm Hg) 135 6 2.4 133 6 2.4 109 6 4.8*† 108 6 7.8*† 124 6 4.1*†‡ 117 6 3.4*†
Rate–pressure product (mm Hg 3
min21 3 1023)
33.2 6 0.6 30.0 6 0.6* 24.7 6 1.9*† 17.5 6 3.4*†‡ 32.4 6 1.2‡§ 29.4 6 0.3*‡§
Cardiac output (ml/min) 60.4 6 1.0 50.3 6 1.0* 38.8 6 1.6*† 33.8 6 2.4*†‡ 52.6 6 1.7*‡§ 45.9 6 1.5*‡§
Hydraulic work (mm Hg 3 ml 3
min21 3 1022)
81.4 6 2.2 66.6 6 1.5* 42.3 6 3.1*† 37.6 6 4.5*† 65.3 6 3.9*‡§ 53.6 6 1.8*†‡§\
Coronary flow (ml/min per g
wet weight)
16.4 6 0.9 11.4 6 0.6* 12.4 6 1.0* 6.9 6 1.0*†‡ 16.3 6 1.0†‡§ 11.7 6 0.5*§\
Significant differences (p , 0.05) are indicated as *versus preischemic control hearts; †versus preischemic hypertrophy hearts; ‡versus reperfused untreated control hearts; §versus
reperfused untreated hypertrophied hearts; \versus reperfused DCA-treated control hearts. Data are presented as mean value 6 SEM. Values were obtained at the end of 30 min
of preischemic perfusion (Before Ischemia) or at the end of 60 min reperfusion (Reperfusion).
DCA 5 dichloroacetate.
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(Fig. 2). During reperfusion, rates of glycolysis in untreated
control and hypertrophied hearts did not differ from corre-
sponding preischemic values. Glycolytic rates were not
significantly altered by DCA in control hearts during
reperfusion (Fig. 2). However, rates of glycolysis were
significantly reduced by DCA during reperfusion in hyper-
trophied hearts, as compared with values in untreated
hypertrophied hearts and in hypertrophied hearts before
ischemia (Fig. 2). As during reperfusion, glycolysis was
decreased by DCA in nonischemic hypertrophied hearts,
but not in nonischemic control hearts (Table 2).
GLUCOSE OXIDATION. During the preischemic period,
rates of glucose oxidation tended to be lower in hypertro-
phied hearts than in control hearts, but the difference was
not significant (Fig. 3). As with glycolytic rates, glucose
oxidation rates in untreated control and hypertrophied
hearts during reperfusion were not different from corre-
sponding preischemic values (Fig. 3). However, glucose
oxidation during reperfusion was significantly depressed in
untreated hypertrophied hearts as compared with untreated
control hearts (Fig. 3). Glucose oxidation during reperfu-
sion was significantly increased by DCA in both control and
Figure 1. Mechanical function of untreated control (open circles) and hypertrophied (open squares) hearts and DCA-treated control (solid circles) and
hypertrophied hearts (solid squares) during preischemic perfusion and reperfusion after ischemia (n 5 6 to 13 per group). Significant differences (p , 0.05)
are indicated as *versus untreated preischemic control hearts; #versus untreated preischemic hypertrophied hearts; †versus reperfused untreated control
hearts; ‡versus reperfused untreated hypertrophied hearts.











Heart rate (beats/min) 258 6 6 229 6 13* 250 6 14 217 6 14*
Peak systolic pressure (mm Hg) 124 6 3 117 6 3 134 6 2*† 135 6 4*†
Rate–pressure product
(mm Hg 3 min21 3 1023)
31.9 6 1.1 26.7 6 1.0* 33.5 6 2.4† 29.2 6 1.3‡
Cardiac output (ml/min) 71.5 6 0.3 57.0 6 1.8* 73.8 6 1.4† 64.0 6 1.8*†‡
Hydraulic work (mm Hg 3 ml 3
min21 3 1022)
88.3 6 2.7 66.8 6 2.2* 98.9 6 3.2*† 86.5 6 2.2†‡
Coronary flow (ml/min per g wet weight) 21.8 6 1.0 11.2 6 1.4* 20.3 6 1.0† 15.4 6 0.3*†‡
Glycolysis (nmol/min per g dry weight) 2,352 6 102 3,243 6 205* 1,923 6 149† 2,077 6 160†
Glucose oxidation (nmol/min per g dry weight) 235 6 24 200 6 22 402 6 24*† 366 6 16*†
H1 production (nmol/min per g dry weight) 4,234 6 220 6,086 6 176* 3,042 6 453*† 3,421 6 375*†
Significant differences (p , 0.05) are indicated as *versus untreated control hearts; †versus untreated hypertrophy hearts; ‡versus DCA-treated control hearts. Data are presented
as mean value 6 SEM. Functional variables were obtained at the end of the 30 min of nonischemic perfusion.
DCA 5 dichloroacetate.
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hypertrophied hearts, as compared with preischemic values
or with values in untreated control and hypertrophied hearts
during reperfusion. Glucose oxidation rates during reperfu-
sion in DCA-treated hypertrophied hearts were lower, but
not significantly, than rates in DCA-treated control hearts
(Fig. 3). Dichloroacetate treatment also increased glucose
oxidation nearly twofold in nonischemic control and hyper-
trophied hearts (Table 2).
Myocardial glycogen. Glycogen did not differ significantly
between control and hypertrophied hearts before ischemia
(control 95 6 4 vs. hypertrophy 101 6 2 mmol/g dry
weight, p 5 NS). During ischemia, glycogen decreased to
comparable values in control and hypertrophied hearts
(control 63 6 5 vs. hypertrophy 64 6 6 mmol/g dry weight,
p 5 NS). Glycogen was resynthesized to similar but slightly
different degrees in all groups during reperfusion (control
100 6 2 vs. control 1 DCA 109 6 2 mmol/g dry weight,
p , 0.05; hypertrophy 107 6 3 vs. hypertrophy 1 DCA
115 6 4 mmol/g dry weight, p , 0.05).
DISCUSSION
Dichloroacetate, contractile function and glucose oxida-
tion. The beneficial effects of DCA on functional recovery
of nonhypertrophied hearts after ischemia are well described
(9–14). The improved postischemic function of nonhyper-
trophied hearts produced by DCA has been associated with
and attributed to a stimulation of glucose (and pyruvate)
oxidation (9–14). The current study demonstrates that this
association also occurs in the reperfused ischemic hypertro-
phied heart (Tables 1 and 3, Fig. 1 and 3). Dichloroacetate
stimulates glucose oxidation because it activates PDH, a
mitochondrial multienzyme complex that oxidatively decar-
boxylates pyruvate to form carbon dioxide, reduced nicotin-
Figure 2. Rates of glycolysis in untreated control (open bar) and hypertrophied (solid bar) hearts and DCA-treated control (hatched bar) and
hypertrophied hearts (stippled bar) during preischemic perfusion (Before Ischemia) and reperfusion after ischemia (Reperfusion) (n 5 6 to 13 per group).
Significant differences (p , 0.05) are indicated as *versus untreated preischemic control hearts; #versus untreated preischemic hypertrophied hearts; †versus
reperfused untreated control hearts; ‡versus reperfused untreated hypertrophied hearts.















Peak systolic pressure (mm Hg) 139 6 4 146 6 5 114 6 9*† 89 6 7*† 117 6 7*† 117 6 2*†§
Cardiac output (ml/min) 71.7 6 1.9 48.3 6 2.0* 37.0 6 5.7* 24.5 6 4.4*† 60.6 6 4.0‡§ 39.2 6 5.0*\
Hydraulic work (mm Hg 3 ml 3
min21 3 1022)
99.7 6 3.5 70.8 6 3.8* 42.8 6 8.9*† 22.2 6 4.6*†‡ 71.3 6 7.2*‡§ 45.8 6 6.3*†§\
Coronary flow (ml/min per g
wet weight)
17.7 6 1.2 10.5 6 0.8* 10.7 6 1.2* 6.6 6 1.2*†‡ 19.0 6 2.0†‡§ 10.6 6 1.5*\
Significant differences (p , 0.05) are indicated as *versus preischemic control hearts; †versus preischemic hypertrophy hearts; ‡versus reperfused untreated control hearts; §versus
reperfused untreated hypertrophied hearts; \versus reperfused DCA-treated control hearts. Data are presented as mean value 6 SEM. Values were obtained at the end of 30 min
of preischemic perfusion (Before Ischemia) or at the end of 60 min reperfusion (Reperfusion).
DCA 5 dichloroacetate.
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amide adenine dinucleotide (NADH2) and acetyl coenzyme
A (7,8). The activity of PDH is a major determinant of the
extent of myocardial glucose oxidation (7,8). Activity of
PDH is regulated by reversible phosphorylation of PDH
and by end-product inhibition by acetyl coenzyme A and
NADH2 (7,8). Phosphorylation by pyruvate dehydrogenase
kinase (PDK) inactivates the PDH complex, whereas de-
phosphorylation by pyruvate dehydrogenase phosphatase
leads to reactivation (7,8). Dichloroacetate activates PDH
by inhibiting PDK (18,19), thereby stimulating glucose
oxidation.
Dichloroacetate and glycolysis. In the absence of DCA,
rates of glycolysis before and after ischemia were accelerated
in hypertrophied as compared with nonhypertrophied hearts
(Fig. 2, Table 2)—a finding in keeping with previous
observations (3,4,15,20–22). This observation is also con-
sistent with findings in hearts exposed to a pressure overload
where the in vitro activity of a number of glycolytic enzymes
is increased, as compared with nonhypertrophied hearts
(23), and isoenzymes of lactate dehydrogenase (24), enolase
(25) and creatine kinase (26) shift toward more anaerobic,
fetal forms.
Activation of glucose (and pyruvate) oxidation is expected
to lead to a corresponding decrease in glycolytic flux
(Pasteur effect) in the presence of a constant or lowered
energy demand. Experimentally, however, the effect of
DCA on glycolysis in nonischemic and reperfused nonhy-
pertrophied hearts has been variable—sometimes inhibiting
glycolysis (9) and sometimes having no effect (11). In the
studies reported here, DCA inhibited glycolysis during
nonischemic perfusion and reperfusion, but only in hyper-
trophied hearts (Fig. 2, Table 2). It has been proposed that
DCA may directly inhibit glycolysis by reducing the activ-
ities of hexokinase and pyruvate kinase (27)—two enzymes
in the glycolytic pathway. This possibility was not assessed
in the current study. The explanation for the difference
between the effect of DCA on glycolysis in control and
hypertrophied hearts remains to be determined.
Contractile function and myocardial H1 production.
Despite an acceleration of glycolytic rates in untreated
hypertrophied hearts, there was no corresponding increase
in the rates of glucose oxidation (Fig. 2 and 3, Table 2). In
fact, the rates of glucose oxidation during reperfusion in
untreated hypertrophied hearts were lower than those in
untreated control hearts. The mechanism(s) responsible for
depressed rates of glucose oxidation in untreated hypertro-
phied hearts are not yet known. Of interest, our very recent
experiments suggest that alterations in PDH cannot account
entirely for the low rates of glucose oxidation in hypertro-
phied hearts (28). Regardless of the mechanism, a dramatic
uncoupling between glycolysis and glucose oxidation was
observed in hypertrophied hearts that was substantially
greater than that seen in control hearts. A glucose molecule
passing through glycolysis leads to the production of 2 H1,
by way of adenosine triphosphate (ATP) hydrolysis, and a
molecule of glucose oxidized to carbon dioxide results in no
net H1 production (9). As such, H1 production, calculated
from rates of glycolysis and glucose oxidation (9), was
accelerated in untreated hypertrophied hearts as compared
with untreated control hearts before and after ischemia (Fig.
Figure 3. Rates of glucose oxidation in untreated control (open bar) and hypertrophied (solid bar) hearts and DCA-treated control (hatched bar) and
hypertrophied hearts (stippled bar) during preischemic perfusion (Before Ischemia) and reperfusion after ischemia (Reperfusion) (n 5 6 to 13 per group).
Significant differences (p , 0.05) are indicated as *versus untreated preischemic control hearts; #versus untreated preischemic hypertrophied hearts; †versus
reperfused untreated control hearts; ‡versus reperfused untreated hypertrophied hearts.
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4). Importantly, the absence of differences in glycogen
degradation between control and hypertrophied hearts dur-
ing ischemia indicates that the proton burden arising from
glycogen catabolism during no-flow ischemia did not differ
between the two groups.
We hypothesize that excess H1 production, arising from
alterations in glucose metabolism, is responsible for greater
dysfunction of hypertrophied hearts as compared with
nonhypertrophied hearts during reperfusion. Accumulation
of H1 in the myocardium can interfere with contractile
function directly (29). It can also cause influx and intracel-
lular accumulation of Na1 and Ca21 by means of Na1/H1
and Na1/Ca21 exchange (6,9,10,30). The influx of Na1
and Ca21 that occurs secondary to clearance of H1 may
reduce contractile function and cardiac efficiency (cardiac
work/oxygen consumed) by redirecting ATP toward pro-
cesses involved in cellular ion transport and away from those
involved in contractile function or by leading to myocardial
damage, or both (6,9,10,31). Importantly, hypertrophied
hearts have alterations in transport processes responsible for
Na1 and Ca21 homeostasis (6). Many of these alterations
potentiate the detrimental effects of Na1 and Ca21 influx
and accumulation, especially during reperfusion. In keeping
with this scenario, impaired recovery of hypertrophied
hearts during reperfusion has been shown to be associated
with exaggerated Ca21 and Na1 overload (2,32).
Dichloroacetate and myocardial H1 production. In the
current study, H1 production in the hypertrophied heart
was dramatically reduced by DCA, because glucose oxida-
tion was stimulated and glycolysis was inhibited (Fig. 2
through 4, Table 2). This reduction in H1 production, and
its resultant effects on myocardial ion concentrations, was
likely a key factor in the functional improvements observed
in DCA-treated hypertrophied hearts, particularly during
reperfusion. In support of this view, we have shown that a
Na1/H1 exchange inhibitor can mimic the effects of DCA
in nonhypertrophied hearts perfused under identical condi-
tions (11). Furthermore, we have recently shown that DCA,
given at reperfusion, stimulates glucose oxidation, decreases
H1 production, increases the rate of recovery of intracellular
H1 concentration (pHi) and enhances postischemic recov-
ery of nonhypertrophied hearts (33). However, direct mea-
surement of changes in pHi and Na1 and Ca21 concentra-
tion during reperfusion of hypertrophied hearts, as well as
demonstration that inhibitors of Na1/H1 exchange provide
similar benefit, will be required to prove that this view is
correct. That some variables of contractile function were
lower in hypertrophied hearts than in nonhypertrophied
hearts in the presence of DCA (Tables 1 through 3) may
have resulted from several factors, including lower rates of
coronary flow and glucose oxidation as well as alterations in
ion pumps and channels (6) in hypertrophied hearts.
Other potential effects of dichloroacetate. Dichloro-
acetate may have also improved postischemic function by
alternative, but not necessarily mutually exclusive, mecha-
nisms. The beneficial effect of enhanced glucose oxidation
may also be due to increases in the intramitochondrial
NADH2/oxidized nicotinamide adenine dinucleotide
(NAD) ratio, which would thereby increase the mitochon-
drial oxidative phosphorylation potential (13). The DCA-
Figure 4. Rates of H1 production from glucose metabolism in untreated control (open bar) and hypertrophied (solid bar) hearts and DCA-treated control
(hatched bar) and hypertrophied (stippled bar) hearts during preischemic perfusion (Before Ischemia) and reperfusion after ischemia (Reperfusion) (n 5
6 to 13 per group). Significant differences (p , 0.05) are indicated as *versus untreated preischemic control hearts; #versus untreated preischemic
hypertrophied hearts; †versus reperfused untreated control hearts; ‡versus reperfused untreated hypertrophied hearts. H1 production arising from glucose
metabolism was calculated by subtracting the rate of glucose oxidation from the rate of glycolysis and multiplying by 2 (9).
1384 Wambolt et al. JACC Vol. 36, No. 4, 2000
Effects of DCA in Postischemic Hypertrophied Rat Hearts October 2000:1378–85
induced improvement in coronary flow during reperfusion
may also have been a contributing factor (Tables 1 through 3).
Conclusions. We show for the first time, to our knowl-
edge, that DCA normalizes postischemic function of hy-
pertrophied rat hearts in association with stimulation of
glucose oxidation and inhibition of glycolysis. These find-
ings support the hypothesis that excess H1 production,
arising from high glycolytic rates and low glucose oxidation
rates, is responsible for the greater dysfunction of hypertro-
phied hearts as compared with nonhypertrophied hearts
during reperfusion. Furthermore, the data also indicate that
pharmacologic modulation of the activity of pyruvate dehy-
drogenase in hypertrophied hearts may be a therapeutically
useful approach to improve function of the hypertrophied
heart in the setting of ischemia and reperfusion.
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